GIA
SPRY icon

GHP Investment Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

GHP Investment Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25 Hold
3
– – ﹤0.01% 1379
2026
Q1 		$25 Buy
+3
New +$29 ﹤0.01% 1420

Other funds holding SPRY

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

GHP Investment Advisors's SPRY Position: Q2 2026 in Review

GHP Investment Advisors held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 3 shares worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #1379.

GHP Investment Advisors first reported a position in SPRY in Q1 2026 and has held it in 2 quarters since. 31 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • GHP Investment Advisors held 3 shares of ARS Pharmaceuticals worth $25 as of Q2 2026.
  • GHP Investment Advisors left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #1379 holding.
  • GHP Investment Advisors first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 31 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.